Bio-Society Issues and Related Processes
(Andreas Seiter, Novartis (Switzerland))
Andreas Seiter explained the need for a multi-stakeholder approach from an industry’s perspective, based on the example of “access to healthcare”. He gave a brief definition of the term “bio-society issues”, involving:
The challenge of bio-innovation lies in the disruptive change, which creates fears like loss of status, economic disadvantage and increasing external control of our lives. Bio-society issues have a potentially major impact on the fundamentals of human society. The goal of achieving equal access to live-saving medicines for all becomes more difficult to achieve if such medicines become a reality in increasing numbers - but at high costs.
The genomics revolution, the North-South divide and an aging society create a mix of conditions, which threatens a (remaining) consensus. A refined and more sustainable direction of global healthcare policies is necessary. The healthcare industry used to portray itself as a “philanthropic industry” and suddenly finds its business model under public attack.
Governance issues requiring MSPs in this area include: